Operating expenses - Disclosure of Other Operating Income (Expense) (Details) € in Thousands, $ in Millions |
12 Months Ended | |||
|---|---|---|---|---|
|
Dec. 31, 2025
EUR (€)
|
Dec. 31, 2024
EUR (€)
|
Dec. 31, 2024
USD ($)
|
Dec. 31, 2023
EUR (€)
|
|
| Analysis of income and expense [abstract] | ||||
| Other operating expenses | € (21) | € (136) | € (2,542) | |
| Other operating income | 85 | 3 | 0 | |
| Total Other operating income and expenses | 64 | (134) | (2,542) | |
| Disclosure Of Operating Expenses [Line Items] | ||||
| Termination benefits expense | 64 | 129 | 700 | |
| Revenues | € 29,643 | (11,609) | 30,058 | |
| Janssen | ||||
| Disclosure Of Operating Expenses [Line Items] | ||||
| Revenues | € (1,600) | € (1,600) | ||
| Termination of PharmaEngine License and Collaboration Agreement, NBTXR3 | ||||
| Disclosure Of Operating Expenses [Line Items] | ||||
| Contract termination indemnities | $ | $ 1.0 | |||